(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

COMPOSTOS ANTICÂNCER DE DIRECIONAMENTO AO RECEPTOR NUCLEAR HORMONAL

Em AnáliseInvention PatentPCT · US2023075456

Application data

Number

112025005888

Type

Invention Patent

Filing

09/28/2023

Publication

09/30/2025

PCT

US2023075456

Progress at the INPI

Examination not yet requested
  1. Filing09/28/23
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

Examination has not been requested yet. Without that request by 09/28/2026, the application is definitively abandoned (art. 33 of the Brazilian IP Act).

Deadline to request examination:09/28/2026(34 days left)

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 09/30/2025. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

NUVATION BIO INC.

US

See this company's full portfolio

Inventors

C. M. (pessoa física)

US

D. H. (pessoa física)

US

I. D. (pessoa física)

US

Technical data

Priority claims

US

63/377,511 · 09/28/2022

Abstract

COMPOSTOS ANTICÂNCER DE DIRECIONAMENTO AO RECEPTOR NUCLEAR HORMONAL. A presente invenção refere-se a compostos que compreendem uma carga útil nuclear, tal como um inibidor de topoisomerase, veneno de topoisomerase ou um análogo do mesmo e um epítopo de direcionamento ao receptor nuclear.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de entrada na fase nacional - PCT

#1.3

09/30/2025

RPI 2856

Alteração de dados cadastrais

#1.1

04/08/2025

RPI 2831

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.